Compare Incyte Corporation (INCY) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Sony Group Corp — how do they compare? Incyte Corporation trades at $118.05 (market cap $23.11B), while Sony Group Corp trades at $21.13 (market cap $125.96B). The key difference: Sony Group Corp is far larger — about 5.5× Incyte Corporation's market cap, and Sony Group Corp pays a 0.75% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | SONY | |
|---|---|---|
Market Cap | $23.11B | $125.96B |
Sector | Health | Technology |
52-Week High | $118.52 | $30.26 |
52-Week Low | $67.38 | $19.32 |
Enterprise Value | $19.13B | $122.45B |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Sony trades at $21.165 with modest daily gains of 0.21%, supported by strong technical momentum and bullish analyst sentiment. The company demonstrates solid fundamentals with $12.96T in revenue and $1.14T net income for 2025, though recent Q1 2026 earnings missed expectations. Sony's entertainment strategy expansion and digital gaming transition position it for long-term growth despite near-term execution risks.
Sony presents a compelling investment case with strong cash flow generation and analyst support, though investors must monitor the digital gaming transition execution and potential revenue volatility. The stock's current valuation metrics appear reasonable given the company's market position and growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
